GeneDx Holdings Corp. Class A Common Stock
WGS
$34.51
-49.20%
GeneDx Holdings Corp. is a healthcare company specializing in genomic information and diagnostics, focusing on pediatric and rare genetic disorders. It is a genomics pioneer aiming to transform healthcare by providing exome and genome sequencing to enable proactive, precision medicine.…
WGS
GeneDx Holdings Corp. Class A Common Stock
$34.51
Investment Opinion: Should I buy WGS Today?
Based on a synthesis of the data, the objective assessment is a Hold for risk-averse investors and a speculative Buy only for those with a high-risk tolerance and a long-term horizon. While the fundamental growth story and analyst targets are compelling, the severe technical damage, lack of current profitability, and premium valuation create significant near-term headwinds. The uniform 'Buy' ratings from analysts reflect a belief in the long-term story, but the current price action suggests the market is demanding proof of execution.
Sign up to view all
WGS 12-Month Price Forecast
The data presents a stark contradiction: strong operational growth against catastrophic price performance. The neutral stance reflects this balance of long-term potential against severe near-term risks. Confidence is medium due to the limited analyst data and high volatility.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GeneDx Holdings Corp. Class A Common Stock's 12-month outlook, with a consensus price target around $44.86 and implied upside of +30.0% versus the current price.
Average Target
$44.86
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$28 - $45
Analyst target range
Wall Street analyst coverage for GeneDx is limited, with only two analysts providing estimates. The consensus estimates for future performance are positive, with an average EPS forecast of $8.76 and average revenue forecast of $1.38 billion. Recent institutional ratings from firms like Guggenheim, Piper Sandler, and BTIG are uniformly positive (Buy/Overweight), indicating analyst confidence in the company's long-term prospects despite recent stock price weakness.
Bulls vs Bears: WGS Investment Factors
GeneDx presents a classic high-risk, high-reward profile. Strong revenue growth and analyst optimism in a transformative market are countered by severe stock price weakness, persistent unprofitability, and a premium valuation. The investment thesis hinges entirely on the company's ability to achieve its forecasted profitability.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 26.5% YoY, indicating robust demand.
- Analyst Confidence: Recent institutional ratings are uniformly positive (Buy/Overweight).
- Solid Financial Health: Current ratio of 2.46 and moderate debt-to-equity of 0.49.
- High-Growth Market Position: Pioneer in genomic diagnostics for rare pediatric disorders.
Bearish
- Severe Price Downtrend: Stock down 47.45% over 6 months, underperforming the market.
- Unprofitability and Negative Margins: Net margin of -14.6% in Q4 2025, swinging to a loss.
- Elevated Valuation Metrics: PS ratio of 8.18 is high given current losses.
- Extreme Volatility: Beta of 2.15 indicates high sensitivity to market swings.
WGS Technical Analysis
The stock has experienced a severe downtrend over the past six months, declining by 47.45% from October 2025 levels. This weakness has accelerated recently, with the price falling 25.22% over the past month and 53.43% over the past three months, significantly underperforming the broader market (SPY). The current price of $59.61 sits near the lower end of its 52-week range of $55.17 to $170.87, representing a drawdown of approximately 65% from its high. The stock exhibits high volatility with a beta of 2.15, and the recent price action suggests persistent selling pressure with no clear signs of a bottom in the near term.
Beta
2.07
2.07x market volatility
Max Drawdown
-79.4%
Largest decline past year
52-Week Range
$33-$171
Price range past year
Annual Return
-47.8%
Cumulative gain past year
| Period | WGS Return | S&P 500 |
|---|---|---|
| 1m | -47.9% | +10.4% |
| 3m | -59.6% | +5.5% |
| 6m | -75.1% | +8.0% |
| 1y | -47.8% | +28.4% |
| ytd | -73.9% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WGS Fundamental Analysis
Revenue growth has been strong on a year-over-year basis, with Q4 2025 revenue of $120.99 million representing a 26.5% increase. However, profitability remains a significant challenge; the company swung to a net loss of $17.67 million in Q4 2025 from a profit of $5.44 million in Q4 2024, with the net margin deteriorating to -14.6%. Financial health appears stable with a current ratio of 2.46 and a moderate debt-to-equity ratio of 0.49. Operational efficiency metrics are weak, with negative returns on assets (-1.55%) and equity (-6.82%) for the latest period, indicating the company is not generating profits from its asset base.
Quarterly Revenue
$120989000.0B
2025-12
Revenue YoY Growth
+0.26%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$14262000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WGS Overvalued?
Given the company's negative net income and EBITDA, the Price-to-Sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 8.18, which is elevated and suggests the market is pricing in significant future growth despite current losses. The forward P/E ratio of 28.98, based on estimated future profits, also indicates a premium valuation. For comparison, the Enterprise Value to Sales (EV/Sales) ratio is 3.95, which provides an alternative market value perspective. No industry average comparison data is available in the provided inputs.
PE
-166.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -102x~95x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
534.9x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is execution risk. The company must convert its strong revenue growth into sustainable profits, a challenge evidenced by its swing to a net loss in Q4 2025 despite higher sales. The elevated Price-to-Sales ratio of 8.18 implies significant future growth is already priced in, leaving the stock vulnerable to any growth slowdown or margin disappointment.
Market and volatility risks are pronounced. With a beta of 2.15, WGS is more than twice as volatile as the broader market, which is problematic during a sustained downtrend. The stock has shown a 65% drawdown from its 52-week high, and high short interest (short ratio 4.78) suggests a skeptical market sentiment that could fuel further declines. The lack of a wide analyst coverage base (only 2 analysts) also reduces visibility and consensus stability.
FAQ
Key risks include: 1) Execution risk: failing to achieve profitability despite 26.5% revenue growth. 2) Valuation risk: the high PS ratio of 8.18 could contract sharply. 3) Volatility risk: a beta of 2.15 leads to large swings. 4) Sentiment risk: the stock is down 47.45% in six months with high short interest (ratio 4.78), indicating persistent negative momentum.
The 12-month outlook is wide-ranging due to high volatility. The base case (50% probability) sees a range of $75-$110, assuming continued growth but ongoing profitability challenges. The bull case (25%) targets $130-$170 if profitability aligns with the $8.76 EPS forecast. The bear case (25%) aligns with the 52-week low, targeting $55-$65 if growth stalls and losses mount.
Based on traditional metrics, WGS appears overvalued. With a negative P/E and a high Price-to-Sales ratio of 8.18, the market is pricing in significant future growth that has not yet materialized in profits. The forward P/E of 28.98 also suggests a premium. It is undervalued only if one believes the company will quickly achieve its analyst-forecasted EPS of $8.76.
WGS is a high-risk, high-potential stock. It could be a good buy for aggressive, long-term investors who believe in the genomic diagnostics story and can tolerate volatility, as evidenced by its 2.15 beta and 65% drawdown. However, its current lack of profitability (net margin -14.6%) and premium valuation (PS ratio 8.18) make it a poor choice for conservative or short-term investors.
WGS is suitable only for long-term investment (5+ years). The short-term outlook is clouded by severe price weakness (-53.43% over 3 months) and a lack of current profits. The company's thesis—transforming healthcare through genomics—will take years to play out. Short-term traders would be exposed to excessive volatility without the fundamental catalyst of profitability to drive near-term gains.